Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a…..
GTP Bioways is acquiring IDBiotech and invests €12M in two GMP biopharmaceutical production units Acquisition of CRO IDBiotech GTP Bioways, a French CDMO (Contract Development and Manufacturing Organization) specializing in the production of biotherapies and nanotherapies, has acquired IDBiotech. Based in Issoire (France), this CRO specialises in the development…..
Second phase II study for zilebesiran, an RNAi therapeutic for the treatment of hypertension Alnylam Pharmaceuticals, a leading RNAi therapeutics company, has initiated KARDIA-2 (NCT05103332), a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen…..
First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™) for the treatment of myotonic dystrophy type 1 (DM1) Avidity Bioscience, a californian biotech company committed to delivering a new class of RNA therapeutics, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with its lead…..
A new European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases Members of the European Platform for Neurodegenerative Diseases (EPND) will embark on a venture to establish a collaborative platform for efficient sample and data sharing, leveraging and linking existing European research infrastructures to accelerate the…..
New technology allows molecules to enter cells safely Professor Braeckmans from Ghent University focused the last ten years on a method for safe engineering of therapeutic cells with photothermal nanofibers. Now, Nature Nanotechnology gives insight in how these biocompatible photothermal nanofibers were developed, and how, upon laser irradiation, cells…..
New large-scale DNA manufacturing facility in the UK Touchlight, a UK-based manufacturer of synthetic DNA, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of…..
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three…..
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France Boehringer Ingelheim announced an additional €100 million investment in its veterinary public health capabilities in Lyon-Jonage, France, to aid governments and public health organizations in managing future emerging and transboundary diseases. Transboundary and emerging diseases are…..
Germany approves Rheacell's cell therapy product Amesanar® for the use in patients with chronic wounds Chronic wounds not only put great strain on the health system, but also have a major impact on the quality of life of affected patients. Rheacell, a German biopharmaceutical company focused on clinical development of…..
- Page Précédente
- 1
- 2
- 3
- 4
- 5
...
- 34
- Page Suivante
Partenaires
